Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 3
1991 1
1992 1
1993 1
1994 1
1996 1
1998 1
1999 3
2000 4
2002 1
2003 4
2004 2
2005 1
2007 2
2008 3
2009 5
2010 4
2011 3
2012 3
2013 2
2014 3
2015 3
2016 1
2017 1
2018 2
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Results by year
Filters applied: . Clear all
Page 1
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
Sonneveld P, et al. J Clin Oncol 2012 - Clinical Trial. Among authors: van Marwijk-Kooy M, van der Velde H, van der Holt B. PMID 22802322
Maintenance consisted of thalidomide 50 mg (VAD) once per day or bortezomib 1.3 mg/m(2) (PAD) once every 2 weeks for 2 years. ...
Maintenance consisted of thalidomide 50 mg (VAD) once per day or bortezomib 1.3 mg/m(2) (PAD) once every 2 weeks for 2 years. ...
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Wester R, et al. Haematologica 2019. Among authors: van Marwijk Kooy M, van der Holt B. PMID 30948492 Free PMC article.
Induction therapy consisted of four cycles of carfilzomib 20/27 mg/m(2) (n=50), 20/36 mg/m(2) (n=20), 20/45 mg/m(2) (n=21), and 20/56 mg/m(2) (n=20) on days 1, 2, 8, 9, 15, 16 of a 28-day cycle; thalidomide 200 mg on day 1 through 28 and dexamethasone 40 mg weekly. ...
Induction therapy consisted of four cycles of carfilzomib 20/27 mg/m(2) (n=50), 20/36 mg/m(2) (n=20), 20/45 mg/m(2) (n= …
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Sonneveld P, et al. Blood 2015 - Clinical Trial. Among authors: van Marwijk-Kooy M, van der Holt B. PMID 25398935 Free PMC article.
During KTd induction therapy, patients received 4 cycles of carfilzomib 20/27 mg/m(2) (n = 50), 20/36 mg/m(2) (n = 20), 20/45 mg/m(2) (n = 21), or 20/56 mg/m(2) (n = 20) on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle; thalidomide 200 mg on days 1 to 28; and dexamethasone 20 mg on days 1, 2, 8, 9, 15, and 16. After autologous stem cell transplantation, patients proceeded to KTd consolidation therapy, where the target doses of carfilzomib were 27 mg/m(2), 36 mg/m(2), 45 mg/m(2), or 56 mg/m(2), respectively, and thalidomide 50 mg. ...
During KTd induction therapy, patients received 4 cycles of carfilzomib 20/27 mg/m(2) (n = 50), 20/36 mg/m(2) (n = 20), 20/45 …
[A man with neutropenic fever]
Ham JC, et al. Ned Tijdschr Geneeskd 2013. Among authors: van Marwijk Kooy MR. PMID 23515043 Dutch.
50 results
Jump to page
Feedback